Most of the angiogenesis inhibitors clinically used in cancer treatment target the vascular endothelial growth factor (VEGF)/ VEGF receptor (VEGFR) pathway. However, the current strategies for treating angiogenesis have limited efficacy. The issue of how to treat angiogenesis and endothelial dysfunction in cancer remains a matter of substantial debate. Here we demonstrate a glycosylation-dependent regulatory mechanism for tumor angiogenesis. St6gal1 −/− mice, lacking the α2,6-sialylation enzyme, were shown to exhibit impaired tumor angiogenesis through enhanced endothelial apoptosis. In a previous study, St6gal1 −/− endothelial cells exhibited a reduction in the cell surface residency of platelet endothelial cell adhesion molecule (PECAM). In this study, we found that cooperative functionality of PECAM-VEGFR2-integrin β3 was disturbed in St6gal1 −/− mice. First, cell surface PECAM-VEGFR2 complexes were lost, and both VEGFR2 internalization and the VEGFR-dependent signaling pathway were enhanced. Second, enhanced anoikis was observed, suggesting that the absence of α2,6-sialic acid leads to dysregulated integrin signaling. Notably, ectopic expression of PECAM increased cell surface integrin-β3, indicating that the reduction of cell surface integrin-β3 involves loss-of-endothelial PECAM. The results suggest that the cell surface stability of these glycoproteins is significantly reduced by the lack of α2,6-sialic acid, leading to abnormal signal transduction. The present findings highlight that α2,6-sialylation is critically involved in endothelial survival by controlling the cell surface stability and signal transduction of angiogenic molecules, and could be a novel target for antiangiogenesis therapy.
Introduction
Tumor angiogenesis inhibitors, which mainly target the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway, have increased the progression-free survival of many cancer patients, but their efficacy in terms of overall survival is relatively modest [1, 2] . Resistance to anti-angiogenic therapy can be partly explained by metabolic reprogramming of tumors in the hypoxic microenvironment [3] . A series of endothelial responses, including rearrangement of cell adhesion molecules [4] , is also considered to be an important factor.
Endothelial cells are heavily covered with a carbohydrate-rich layer, the glycocalyx, which is connected to the endothelium through proteoglycans and glycoproteins [5] . Interactions between endothelial glycans and platelet and leukocyte selectins are involved in the initial attachment of leukocytes and platelets to the endothelial surface, thereby supporting inflammation processes, immune responses, and homeostasis [6] . However, there is limited information available on how glycosylation of growth factor receptors and cell adhesion molecules affects physiological and pathological angiogenesis [7] . A recent exciting observation is that tumor-derived galectin-1 binds to Nglycans of VEGFR2 and activates VEGF-like signaling to preserve angiogenesis [8] . Another interesting report showed that VEGF-dependent proliferation is dependent on heparan sulfate, a component of the functional VEGFR2 complex [9, 10] . These findings raise awareness about the importance of glycosylation-dependent VEGFR2 functionality. Several reports have shown that cytokine treatment elevates α2,6-sialylation on N-glycans in endothelial cells [11, 12] . The sialidase Neu1 removes α2,6-sialic acids from PECAM, thereby disrupting endothelial tube formation activity [13] . Moreover, lack of α2,6-sialylation enhances vascular cell adhesion molecule (VCAM)-1-dependent adhesion [14] , suggesting that endothelial adhesion properties are dynamically controlled by α2,6-sialylation.
VEGFR2 forms functional complexes with integrin-β3 as a critical regulator of pathological angiogenesis [15] , and with PECAM and vascular endothelial cell cadherin as a shear stress sensor [16] . Furthermore, there is growing evidence that homophilic and heterophilic PECAM interactions are both important in the transduction of antiapoptotic signals to cells [17] [18] [19] [20] . PECAM has several α2,6-sialylated N-glycans and has recently been shown to exhibit a lectin activity specific for α2,6-sialylated glycans [21, 22] . Even though these N-glycosylation sites show species-specific differences [23] , several N-glycans are located at the homophilic-binding interface within Nterminal Ig domain 1 and 2 [24] , suggesting that α2,6-sialylated glycans can modulate homophilic PECAMdependent interactions. Moreover, a lack of α2,6-sialylation reduces the cell surface stability of PECAM and increases its sensitivity to mitochondria-dependent apoptotic stimuli [4, 22] . Taken together, there is a possibility that α2,6-sialylation may regulate the cooperative functions of PECAM-VEGFR2-integrin-β3 at the cell surface.
In this study, we found that α2,6-sialic acid-deficient mice exhibit impaired tumor angiogenesis through enhanced endothelial apoptosis. Our study raises the possibility that α2,6-sialylation-dependent angiogenic complex formation could be a novel therapeutic target for inhibition of tumor angiogenesis. 
Results

Tumor angiogenesis is impaired in St6gal1
−/− mice First, to investigate how ST6Gal I deficiency affects tumor growth in vivo, mouse Lewi lung carcinoma (LLC) cells were subcutaneously implanted into St6gal1 +/+ and St6gal1 −/− mice. Tumor growth was observed to be similar between the two types of mice until 10 days after implantation (Fig. 1a) . After 2 weeks, however, the tumor expansion was significantly retarded in St6gal1 −/− mice (Fig. 1a, b) . Histological examination of tumor sections revealed that the necrotic area ratio was significantly higher in the tumors from St6gal1 −/− mice (Fig. 1c, d ). As failure of neovascularization in proliferated tumors results in necrosis of tumor cells [25] , we expected that tumor angiogenesis would be impaired in St6gal1 −/− mice. Von
Willebrand Factor (VWF) immunostaining to identify the endothelium revealed that intratumor vessel formation was poorly observed in St6gal1 −/− mice (Fig. 1e, f) . As St6gal1 −/− mice grow normally and exhibit no tissue abnormalities [26] , it seemed that tumor angiogenesis, but not physiological angiogenesis, was impaired in these mice.
Endothelial apoptosis is enhanced in tumors from
St6gal1
−/− mice Elevated ST6Gal I expression in cancer cells is frequently associated with poor clinical status [27] . We first confirmed that similar levels of perinuclear ST6Gal I expression were seen in LLC cells grown in St6gal1 +/+ and St6gal1 −/− mice (Fig. 2a) . Because relatively high-ST6Gal I expression is observed in vascular endothelial cells [11, 21] , we considered that the impaired tumor angiogenesis in St6gal1 −/− mice could arise through enhanced endothelial apoptosis. Thus, we examined the cleaved fragment of poly(ADPribose)polymerase (PARP), a sensitive apoptotic marker [28] , and vascular endothelial marker PECAM in the tumors from the two types of mice. More tumor vessels from St6gal1 −/− mice were found to be positive for cleaved PARP fragment (Fig. 2b, c) . We then examined the sensitivity of St6gal1 −/− endothelial cells to various apoptotic stimuli. By addition of the LLC cell culture medium to mimic the tumor environment, St6gal1 −/− endothelial cells exhibited markedly higher caspase-3/7 activity (Fig. 2d) . Furthermore, in addition to staurosporine (STSP), an intrinsic mitochondria-dependent apoptotic inducer, the extrinsic apoptotic inducer Fas ligand also induced higher caspase-3/7 activity in St6gal1 −/− endothelial cells (Fig. 2d, e). It is known that PECAM has a protective function against intrinsic but not extrinsic apoptotic stimuli [21] . We therefore hypothesized that a lack of α2,6-sialic acid, a PECAM lectin ligand, could result in a functionally impaired PECAM complex, leading to increased sensitivity to several apoptotic stimuli. We next focused on other endothelial functional molecules modified with α2,6-sialic acids.
Enhanced VEGF/VEGFR2-dependent signaling in St6gal1 −/− endothelial cells VEGFR2 is known to form a functional complex [16] with PECAM and to have α2,6-sialic acids on its N-glycans [8] .
Having confirmed that VEGFR2 contained α2,6-sialic acids by Sambucus sieboldiana agglutinin (SSA)-lectin precipitation analysis (Fig. 3a) , we investigated how endothelial α2,6-sialylation affected VEGF/VEGFR2 signaling. As VEGF is a major factor for promotion of angiogenesis both in vitro and in vivo [29] , we first performed cell migration assays using St6gal1 +/+ and St6gal1 −/− endothelial cells in the presence of VEGF and found that St6gal1 −/− cells exhibited a threefold higher migration rate (Fig. 3b, c) .
Next, we performed in vitro tube formation assays using both types of endothelial cells seeded on Matrigel with VEGF. Both cell types formed a closely knitted meshwork of capillary-like structures at 6 h after stimulation, but only St6gal1 −/− endothelial cells formed loose capillary-like structures at 3 h (Fig. 3d) . Quantitative analyses revealed that the tube length was significantly longer in St6gal1
cells at 3 h after stimulation (Fig. 3e) . Taken together, we concluded that VEGF-dependent signaling was enhanced by the lack of α2,6-sialylation. Because, a recent report showed that VEGFR2 endocytosis critically couples to its downstream signaling [30] , enhanced VEGF-dependent signaling could arise through increased VEGFR2 internalization in St6gal1 −/− cells. As uptake of VEGF-A is largely mediated by VEGFR2 [30] , we compared the uptake of fluorescently labeled VEGF-A in St6gal1 +/+ and St6gal1 −/− endothelial cells. Significantly higher numbers of spots corresponding to internalized VEGF-A were observed in the perinuclear region of St6gal1 −/− endothelial cells (Fig. 4a, b) . A positive feedback mechanism exists, whereby VEGFR2 expression is upregulated through interaction with VEGF and translocates itself to the nucleus [31] . We found that the expression levels of VEGFR2 and PECAM were similar in freshly isolated endothelial cells from St6gal1 +/+ and St6gal1 −/− mice (Fig. 4c) . After both types of endothelial cells were cultured in the presence of VEGF for 2 weeks, the expression level of VEGFR2, but not PECAM, in St6gal1 −/− cells was upregulated by twofold compared with that in
+/+ cells. These results also support our finding of enhanced VEGF/VEGFR2 signaling in the absence of α2,6-sialic acids. Reduction of the cell surface stability of PECAM, a molecular partner of VEGFR2 [16] , could be one of the underlying molecular mechanisms for the enhanced VEGFR2 internalization in St6gal1 −/− cells [21] . To examine the neighbors of PECAM protein that are even weakly associated with one another, we applied the enzyme-mediated activation of radical sources (EMARS) assay, a recently established tool to identify co-clustering molecules on the cell surface under living conditions. We used an anti-PECAM antibody, HRP-labeled secondary antibody, and FITC-arylazide [32] in St6gal1 +/+ and cells. However, co-immunoprecipitation experiments showed similar levels of PECAM-VEGFR2 complex in lysed lung microsomes from the two types of mice (Fig. 4e ).
It should be noted that PECAM itself was also labeled with FITC in St6gal1 +/+ cells, but not in St6gal1 −/− cells, indicating a lower level of cell surface PECAM in the absence of α2,6-sialic acid (Fig. 4d ). To directly observe PECAM-VEGFR2 complexes, we performed a polyligation assay (PLA) and found cell surface PECAM-VEGFR2 complexes in the unpermeabilized human umbilical vein endothelial 
-test). d Endothelial cells isolated from WT and St6gal1
−/− mice were stimulated with culture medium from LLC cells, STSP (1 μM), or an anti-Fas antibody (10 μg/ml). After the treatments, the cells were analyzed for their caspase-3/7 activities by microscopic analysis and quantification using the Olympus FV-1000 and FV10-ASW software. Data are presented as the mean ± SEM. Prism 7 software was used for two-way analysis of variance (ANOVA). e WT and KO endothelial cells were stimulated with 10 μg/ml anti-Fas antibody for 6 h, fixed, and immunostained for cleaved caspase-3. Scale bar, 200 μm cells (HUVECs; Fig. 4f ). Permeabilization increased the levels of PECAM-VEGFR2 complex, indicating the presence of intracellular complexes in the steady-state condition. Interestingly, addition of a competitive α2,6-sialylate glycan to inhibit homophilic PECAM interactions markedly increased the levels of intracellular PECAM-VEGFR2 complex in a dose-dependent manner (Fig. 4g ). Taken together, these results suggest that the PECAM-VEGFR2 complex itself is stable in the absence of α2,6-sialic acid, but tends to be more internalized.
α2,6-sialylation retains cell surface integrin to maintain survival signals to the cell
Because enhanced VEGF/VEGFR2 signaling itself cannot explain the impaired tumor angiogenesis in St6gal1
−/− mice, we focused on other α2,6-sialylated molecules, namely integrins (Fig. 3a) . As the integrin-VEGFR2 axis is critically involved in pathological angiogenesis, enhanced internalization of PECAM-VEGFR2 complexes in St6gal1 −/− cells could affect integrin-dependent signaling, leading to inadequate integrin interactions with the extracellular matrix and cell death, known as anoikis [33] . As focal adhesion kinase (FAK) recruitment to focal adhesions and subsequent Tyr 397 autophosphorylation (pFAK-Y397) is a marker for integrin-dependent signaling [34] , we first used an anti-pFAK-Y397 antibody for immunofluorescent staining of St6gal1 +/+ and St6gal1 −/− endothelial cells, and found that focal adhesion formation was increased in the St6gal1 −/− cells (Fig. 5a, b) . Next, to assess the anoikisinduced cell death, St6gal1 +/+ and St6gal1 −/− endothelial cells were plated on polyHEMA-coated plates. Even though both cell types were plated as single cells with uniform density, they started to form spheroid-like aggregations after (Fig. 5c, d ). This result indicates that the lack of α2,6-sialylation caused aberrant integrin signaling, leading to enhanced endothelial cell death. To understand the molecular basis of enhanced apoptosis, we next used an unbiased approach involving a membrane-based antibody array, which simultaneously detects the phosphorylation of 39 mouse receptor tyrosine kinases. Interestingly, significantly increased phosphorylation was observed for epidermal growth factor receptor (EGFR) in the St6gal1 −/− cells (Fig. 5e ). Incidentally, it is known that enzymatic removal of sialic acids from endothelial cells results in the loss-of-homophilic PECAM interaction and enhanced apoptotic signaling [22] . Having found that sialidase treatment led to caspase activation (Fig. 5f ), we confirmed that sialidase treatment of HUVECs also increased EGFR phosphorylation at Y1173 (Fig. 5g) . Since integrins are known to control EGFR signaling [35] , and we have previously found that ST6Gal I overexpression in endothelial cells increases the levels of cell surface integrins and PECAM [21] , we investigated the possibility that ectopic PECAM expression could retain integrin-β3 on the cell surface. When human PECAM was overexpressed in CHO cells lacking the endogenous α2,6-sialylation enzyme, the cell surface integrin-β3 level was increased with or without ST6Gal I expression (Fig. 5h) . We also found that overexpressed PECAM was retained on the surface of CHO cells without ST6Gal I expression. These results indicate that cell surface PECAM was capable of holding integrin-β3 onto the cell surface.
Increased α2,6-sialylation in the proliferated endothelium of gliomas If α2,6-sialic acid is a critical survival factor for intratumor vessel formation, increased α2,6-sialylation in endothelial cells would be observed in the tumors. As neural ST6Gal I expression is negligible [21, 36] , we focused on a brain tumor, in which endothelial α2,6-sialylation is easily detectable with Trichosanthes japonica agglutinin I (TJA-I) lectin. Compared with normal vessels in the brain (Fig. 5i , lower panel), the astrocytic tumors contained glomeruloid neoangiogenic vessels with strong TJA signals (upper panel). This increased α2,6-sialylation in human brain The graph shows the number of positively-stained focal adhesions/cell in the WT and KO cells. **p < 0.01. Student's t-test. c Endothelial cells from WT and KO mice were subjected to anoikis assays. Live and dead cells were detected by calcein-AM (green) and EthD-1 (red), respectively, Typical cell images taken at 0 and 24 h after seeding in polyHEMA-coated plates are shown. Scale bar, 100 μm. d Rates of dead cells were measured. Data are shown as the mean ± SE (n = 3). *p < 0.001 (Student's t-test). e At 30 min after endothelial cells from WT and KO mice were seeded into polyHEMA-coated plates, the cells were lysed and used for a mouse phospho-RTK assay. The relative signal intensity of each spot was quantified as the ratio of pixel intensity to control intensity (100%) and is shown as the mean ± SEM (n = 4). f HUVECs were treated with sialidase, fixed, and stained with an anti-cleaved caspase-3 antibody (red) and DAPI (blue). Arrowheads show typical prominent signals of cleaved caspase-3. g HUVECs were treated with or without sialidase and their cell lysates were immunostained for EGFR, pEGFR-Y1173, and GAPDH (left). Right graph shows the rate of EGFR phosphorylation at Y1173 as the mean ± SEM (n = 3) **P < 0.01 (Student's t-test). h CHO cells overexpressing PECAM and/or ST6Gal I were assessed by flow cytometry to measure the increase of cell surface integrin-β3 and PECAM. **p < 0.01, ***p < 0.001 (Dunnett's multiple comparison test). i Sections of a human brain astrocytoma were stained with hematoxylin and eosin for Fig. 6 Schematic showing how a lack of α2,6-sialylation leads to impaired tumor angiogenesis. A lack of α2,6-sialylation impairs hemophilic PECAM interactions at the endothelial cell surface, leading to enhanced internalization of PECAM-VEGFR2-integrin complexes. Dysregulated VEGFR2-and integrin-dependent signaling results in enhanced endothelial apoptosis and impaired tumor angiogenesis tumor vessels, and the impaired tumor angiogenesis in St6gal1 −/− mice, raise the possibility of developing a novel angiogenic inhibitor targeting α2,6-sialic acid.
Discussion
In this study, we found that α2,6-sialylation deficiency caused aberrant VEGF/VEGFR and integrin-dependent signaling and endothelial apoptosis in tumors, leading to markedly impaired tumor angiogenesis and growth. We showed that St6gal1 −/− cells exhibit enhanced sensitivity to both intrinsic (e.g., STSP-dependent) and extrinsic (e.g., Fas-dependent) apoptotic stimuli. A lack of α2,6-sialylation impairs functionality of the anti-apoptotic molecule, PECAM. Nevertheless, PECAM deficiency does not affect the extrinsic Fas-dependent apoptotic pathway [18] . These results suggest that α2,6-sialylation deficiency could affect several membrane glycoproteins other than PECAM. Because Fas receptor is α2,6-sialylated, we first suspected that the lack of its α2,6-sialylation may enhance sensitivity to Fas-mediated apoptosis, as previously reported in cancer cells [37] . Intracellular trafficking of Fas to the endosomal compartment results in propagation of apoptosis signaling [38] . Even though the limited Fas expression in endothelial cells [39] hampered us from performing biochemical characterization of endothelial Fas, it could be expected that the cell surface stability of Fas would be reduced by a lack of α2,6-sialylation. In St6gal1 −/− endothelial cells, α2,6-sialic aciddependent homophilic PECAM interaction is lost, leading to cell surface instability of the PECAM-VEGFR2 complex, leading in turn to aberrant signal transduction (Fig. 6 ). Even though VEGFR2 is also α2,6-sialylated, the PECAM-VEGFR2 complex is retained in the absence of α2,6-sialic acid or following the addition of an α2,6-sialylated glycan, indicating that a glycan-independent interaction mode dominates. It should be noted that enhanced VEGFR2 signaling stimulated in vitro angiogenesis in St6gal1 −/− endothelial cells, while tumor angiogenesis was significantly impaired in St6gal1 −/− mice. As markedly accelerated cell death was observed in St6gal1 −/− endothelial cells in the anoikis assay, in which integrins play a pivotal role [33] , cell surface instability of integrins can give rise to unligated integrins, which mediate endosomal apoptosis [40] , leading to impaired tumor angiogenesis. Our previous study revealed increased PECAM phosphorylation and recruitment of Src homology 2 domain-containing protein-tyrosine phosphatase 2 to PECAM in the absence of α2,6-sialylation [21] . In this study, our unbiased approach to investigate how anoikis leads to altered phosphorylation in receptor tyrosine kinases identified the phosphorylation of EGFR, which also has been the focus of extensive research into cancer therapeutics to block angiogenesis and metastasis [41, 42] . Interestingly, Morello et al. [35] reported that β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. As one possible underlying mechanism to explain the instability of several surface endothelial glycoproteins, we suggest that loss of the α2,6-sialic acid-specific lectin PECAM from the cell surface results in enhanced internalization of its partner molecules together with PECAM. Our co-immunoprecipitation assay showed that the α2,6-sialic acid-independent PECAM-VEGFR2 complex and ectopic PECAM expression increased cell surface integrin-β3 in an α2,6-sialic acid-independent manner, suggesting that complex formation of PECAM-VEGFR2-integrin-β3 does not require α2,6-sialylation. Given that α2,6-sialyation is involved in the endothelial homophilic PECAM interaction at the cell surface, an interesting possibility is that α2,6-sialyation of PECAM determines the intracellular localization of its partner molecules, such as VEGFR2 and integrin-β3, thereby regulating their signal transduction and endothelial survival. Indeed, ectopic PECAM expression increased the cell surface residency of integrin-β3. Notably, the requirement of α2,6-sialic acid for stable cell surface PECAM expression is a characteristic feature of endothelial cells, considering that overexpressed PECAM was retained on the surface of CHO cells without ST6Gal I expression.
It is well known that α2,6-sialylation of VEGFR2 [8] and integrins [43, 44] abolishes the binding of galectin-1 or -3, while complex formation of these glycoproteins with PECAM increases at the cell surface. Conversely, enhanced galectin-1/3 binding to these glycoproteins in the absence of α2,6-sialic acid results in the formation of an extracellular galectin glycoprotein lattice, which in turn enhances their signal transductions [45] . Therefore, the lectin roles of both PECAM and galectin-1/3 could be mutually effective.
Lack of α2,6-sialylation disturbed both VEGF/VEGFR and integrin signaling, leading to endothelial apoptosis in the tumors. Considering that most of the currently used angiogenic inhibitors target the VEGF/VEGFR signaling pathway, targeting of α2,6-sialylation could be a novel antiangiogenic strategy. Elevated ST6Gal I expression in cancer tissues is generally associated with poorer clinical outcomes [27] . Taken together, these results suggest that the targeting of α2,6-sialylation could lead to a novel and efficient anticancer drug. However, since St6gal1 −/− mice exhibited Bcell abnormality [26] , an ST6Gal I inhibitor might have immunological side effects. We are currently in the process of screening chemical compounds that mimic glycan targets of PECAM in the hope that these compounds will work as PECAM antagonists and angiogenesis inhibitors.
Materials and methods
Human samples
Paraffin sections of a human brain astrocytoma (grade IV) were purchased from US Biomax Inc.
Mice
St6gal1 −/− mice [3] were generously provided by Dr.
Jamey D. Marth (University of California-Santa Barbara).
All animal experiments were carried out in compliance with the Institutional Guidelines for Animal Experiments of RIKEN Institute.
Cell culture and expression plasmids
Endothelial cells were isolated from mouse livers as previously reported elsewhere [21, 46] , except for the use of an anti-CD146 antibody coupled with Dynabeads-sheep antirat IgG (Thermo Fisher), and cultured in DMEM/F12 (Thermo Fisher) containing 10% fetal bovine serum (FBS), and 50 μg/ml endothelial mitogen (Alfa Aesar). LLC cells (LLC1; CRL-1642, ATCC) were cultured in DMEM (Wako) containing 10% FBS. HUVECs (Lonza) were cultured in EBM TM -2 medium (Lonza) containing 2% FBS and EGM TM -2 SingleQuots TM supplements (Lonza), and used within four passages. CHO-K1 cells cultured in α-MEM containing 10% FBS were plated on 10-cm tissue culture dishes, and transfected with human PECAM-pcDNA [22] , human ST6Gal I-pcDNA [21] , or control pcDNA plasmid (5 μg) using polyethyleneimine MAX (Polysciences) as described previously [47] . After 24 h, the transfected cells were collected for further analysis.
Tumor models LLC cells (2 × 10 6 cells) were injected underneath the dorsal skin of age-matched St6gal1 +/+ (wild type; WT) or St6gal1 −/− (knockout; KO) mice (both on a C57BL/6 N background, n = 8 for each), which were obtained by mating St6gal1 +/− parents. The tumors were measured using Vernier calipers, and the volume was calculated every 3 or 5 days using a standard formula (width 2 × length × 0.52) [48] . Mice were killed when tumors reached a volume greater than 5 cm 3 . On day 24, the mice were killed, and their tumors were weighed, fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS), incubated with 30% sucrose in PBS, snap-frozen in Tissue-Tek OCT compound (Thermo Fisher), and stored at −80°C. The same experiments were repeated to prepare paraffinembedded sections. Tumor blocks were cut at 4-µm thickness for paraffin sections and 50-μm thickness for frozen sections.
Real-time PCR
Total RNA was isolated from endothelial cells using TRIzol reagent (Thermo Fisher), and 1 μg of the RNA was reversetranscribed with random hexamers using a SuperScript III First-Strand Synthesis System (Thermo Fisher). The cDNA amplifications and PCR conditions were described previously [49] . The probes for PECAM (Thermo Fisher, Mm01242584_m1) and VEGFR2 (Thermo Fisher, Mm01222421_m1) were labeled with the fluorescent reporter dye FAM at their 5′-end and the quencher MGB at their 3′-end. The probes for rRNA (Thermo Fisher, 4308329) were labeled with VIC at their 5′-end and the quencher dye TAMRA at their 3′-end. The expression levels of the target genes were measured in duplicate and normalized by the corresponding rRNA levels.
Immunohistochemical and histochemical analysis
Paraffin-embedded mouse tumor sections were deparaffinized in xylene for 10 min and rehydrated in an ethanol series (100%, 95%, and 70%) and stained with hematoxylin and eosin for histological examination. For immunohistochemical analysis, frozen sections were blocked with 5% goat serum and incubated with primary and secondary antibodies. Tumor sections stained for VWF were observed with a NanoZoomer Digital Pathology (Hamamatsu Photonics). Tumor sections stained with hematoxylin and eosin were observed with a KEYENCE BZ-X700. Other sections were visualized using an Olympus FV-1000 confocal microscope. Quantitative analysis was performed with Metamorpho software (Molecular device) or FV10-ASW ver. 1.7 software (Olympus). The human brain astrocytoma paraffin sections were autoclaved at 120°C for antigen retrieval. For TJA-I lectin staining, we performed fluorescence-indirect tyramide signal amplification. Briefly, tumor sections were incubated with 3% hydrogen peroxidase in PBS, treated with the blocking solutions supplied in a tyramide signal amplification kit (TSA Biotin System; Thermo Fisher), and then incubated with anti-PECAM antibodies in the blocking solutions overnight at 4°C. After three rinses with PBS for 5 min each, the sections were incubated with biotinylated TJA-I lectin, Alexa 546-donkey anti-mouse and DAPI for 1 h. After three rinses with PBS, tyramide-enhanced immunoreactivity was visualized with horseradish peroxidase-conjugated streptavidin for 1 h and Alexa Fluor 488-conjugated tyramide for 10 min. Detailed descriptions of the primary antibodies, secondary antibodies, and lectins are provided in Supplementary 
PLA
HUVECs plated on collagen-coated 8-well chamber slides were treated with or without α2,6-sialylated biantennary Nglycan (0.5 or 2 mM, Fushimi Pharmaceutical Co.) for 18 h, washed with PBS, and fixed with 4% PFA. For permeabilization, the cells were then treated with 0.3% Triton X-100 in PBS for 30 min, and stained with 7.5 μg/ml anti-PECAM and -VEGFR2 antibodies and with Duolink in situ PLA probe anti-mouse PLUS and -rabbit MINUS (SigmaAldrich). Subsequent procedures were performed according to the manufacturer's protocol.
Flow cytometry
CHO cells overexpressing human PECAM and/or human ST6Gal I were collected and suspended as single-cell suspensions in FACS buffer (1% BSA and 0.1% NaN 3 in PBS). The cells were incubated with primary and fluorescently labeled secondary antibodies for 30 min at 4°C, and then analyzed by flow cytometry in a FACSCalibur (BD Biosciences).
In vitro tube formation assay
Tube formation by endothelial cells from St6gal1 +/+ and St6gal1 −/− mice (three passages each) was assessed as described previously [50] . Unpolymerized Matrigel (BD Biosciences) was diluted with serum-free DMEM/F12 (1:1), aliquoted at 300 μl/well into 24-well plates, and allowed to polymerize for 30 min at 37°C. Cells (2 × 10 5 cells) suspended in 1 ml of medium containing 50 ng/ml mouse VEGF-A (R&D Systems) were seeded on the polymerized gel and incubated for 3-6 h. Tube formation was observed after the addition of 2 μl of calcein-AM (1 mg/ml). Tube length was determined by Angiogenesis Image Analyzer software (KURABO).
Wound healing assay
For wound healing assays, endothelial cells from St6gal1
and St6gal1 −/− mice (three passages each) were seeded in the presence of 50 ng/ml VEGF at a density of 4 × 10 5 cells/ ml in 2-ml culture plates with culture inserts (Ibidi). Images were taken every hour after seeding of the cells. Five representative fields of view were analyzed for each condition and time point.
VEGFR2 internalization
Mouse VEGF-A was labeled with an Alexa Fluor 555 protein labeling kit (Thermo Fisher). Primary liver sinusoidal endothelial cells prepared from St6gal1 +/+ and St6gal1 −/− mice [21] were cultured in serum-free medium for 16 h, and then Alexa-labeled VEGF-A (final concentration, 4 μg/ml) was added to the medium. After 30 min, the cells were washed with warm serum-free medium, and fixed with 4% PFA for microscopic observation.
In vitro induction and quantification of apoptosis
Confluent endothelial cells from St6gal1 +/+ and St6gal1
mice grown on collagen-coated 8-well chamber slides (1.75 × 10 5 cells/well) were treated with 1 μM STSP for 3 h, 10 μg/ml of anti-Fas antibody (#610198, BD Transduction Laboratories) for 6 h, or culture medium from LLC cells for 0.5 h to induce apoptosis [18] . The cells were measured for their caspase-3/7 activities by microscopic analysis and quantification using the Olympus FV-1000 and FV10-ASW ver.1.7 software, respectively.
Anoikis assay
Endothelial cells from St6gal1
+/+ and St6gal1 −/− mice were seeded at 1-5 × 10 5 cells/well in poly(2-hydroxyethyl methacrylate) (polyHEMA, Sigma-Aldrich)-coated 96-well culture plates. After incubation for 0, 2, 6, and 24 h, 1 μg of calcein-AM (Thermo Fisher) and EthD-1 (Thermo Fisher) was added to each well. After 30 min of incubation, live and dead cells were observed by fluorescence microscopy.
Sialidase treatment
HUVECs grown on type I collagen-coated 8-well chamber slides or 10 cm plates were washed three times with Opti-MEM, incubated with V. cholera sialidase in Opti-MEM (10 milliunits/ml, 30 min for immunofluorescence analysis and 25 milliunits/ml, 1 h for western blot analysis), washed with Opti-MEM and with PBS. For immunofluorescence analysis, the cells were then fixed with 4% paraformaldehyde in PBS for 30 min.
Western blotting
Tissue lysates, cell lysates, and immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with primary and horseradish peroxidase (HRP)-labeled secondary antibodies. Signal intensities of the detected bands were quantified using a Luminoimage Analyzer LAS-4000 (GE Healthcare). 
Proteome Profiler RTK Array
EMARS assay
EMARS assays were performed as described previously [32] . Briefly, St6gal1 +/+ and St6gal1 −/− endothelial cells cultured in 10 cm-culture plates were treated with 25 μg of anti-PECAM antibody (MEC13.3) in PBS at 25°C for 20 min. After washing with PBS, the cells were incubated with 15 μg of HRP-conjugated anti-rat antibody and 0.1 mM FITC-arylazide in PBS at 25°C for 20 min. After further washing with PBS, cell lysates were prepared with T-PER buffer containing the protease inhibitor cocktail and reacted with anti-PECAM or anti-FITC antibodies. Immunoprecipitates were analyzed by western blotting.
Statistics
Student's t-tests were performed in Microsoft Excel. Multiple comparison tests were performed using GraphPad Prism.
